Program Outline

Day 1: Biomarker Discovery and Assay Development
Currently, there are many biomarkers for diagnosis of Alzheimer’s disease. However most of them do not provide consistent results.  This session will discuss current research aimed at obtaining reliable biomarkers which could be used to diagnose Alzheimer’s disease at very early stage and also to provide objective and reliable measures of disease progress.

Day 2:  Prevention Strategies and Vaccine Development 
This session will discuss current research into Alzheimer’s Disease prevention including vaccine development. There will be plenty of opportunity for discussion and debate.

Day 3:  Drug Discovery and Development
There are currently no treatments that will stop or reverse the progress of Alzheimer’s disease. With an aging population and increasing number of people with Alzheimer’s, the need to develop ways to halt and treat the disease have become paramount.  This session will discuss current research into Alzheimer’s drug discovery and development including analysis of current clinical trials

Talks include 

• SemiAlloGeneic Vaccines for Alzheimer’s Disease, Professor Mark S. Kindy, Medical University of South Carolina, USA
• New era in AD drug design: intracellular and exosomal targets, Dr Botond Penke, Professor,  University of Szeged, Department of Medical Chemistry, Hungary
• Why have we failed to cure AD , Professor Amos Korczyn, Professor Emeritus, Tel-Aviv University Medical School, Israel
• What did we learn from the first clinical trial of Aβ immunotherapy , Dr Delphine Boche, Senior lecturer (Associate Professor), University of Southampton, UK
• Combining drug-like fragments in multitarget new chemical entities for Alzheimer’s disease, Professor Andrea Cavalli, University of Bologna and Italian Institute of Technology, Italy
• The role of herpes simplex virus type 1 in Alzheimer’s disease, Professor Ruth Frances Itzhaki, University of Manchester, Manchester, UK
• Is AD A Medical Notion of Dementia Worth Keeping in Neuroscience , Professor Fred C. C. Peng, Ph.D. Affiliation: Department of Neurosurgery and Neurological Institute, Taipei Veterans General Hospital, Taiwan
• The biomarkers assessment in a Memory Clinic : is there any added value , Professor Adrian Ivanoiu, MD, PhD, neurologist, Saint Luc University Hospital & Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium
• How to Prevent Dementia and Alzheimer’s, Dr Allen J. Orehek,Innovator/Physician, Dementia Prevention Center, USA
• Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease, Dr Željko M. Svedružić,Assistant Professor, Faculty of Medicine, and Department of Biotechnolgy, Univeristy of Rijeka, Croatia
• Regulatory T cells as new targets for immunotherapy in Alzheimer’s disease , Dr Guillaume Dorothee, Hôpital Saint-Antoine, Paris, France
• Activities of daily living: a new approach to discovering Alzheimer therapies, Dr Robert Deacon, UK
• Cerebrospinal fluid Presenilin-1: a potential new biomarker for Alzheimer’s disease, Dr Javier Sáez-Valero, Professor and Group Leader, Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, & Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
• Investigation of novel functional and metabolic MRI biomarkers for  the preclinical assessment of taupathology in AD, Dr Niall Colgan, Research Associate, UCL Centre for Advanced Biomedical Imaging, London UK
• Eye movement biomarkers in Alzheimer’s disease, Dr Olivier Coubard,The Neuropsychological Laboratory, Paris, France
• Alzheimer’s disease in Down’s syndrome -an ideal model for biomarker discovery  Dr Shahid Zaman, Affiliated Lecturer & Consultant Psychiatrist, University of Cambridge & NHS, UK
• Amyloid hypothesis for AD: Insight from single molecule experiments and computational analyses, Professor Yuri Lyubchenko, University of Nebraska Medical Center, USA
• Going beyond Preclinical Animal Models : Quantitative Systems Pharmacology to support Alzheimer’s Disease Research & Development Dr Hugo Geerts, Chief Scientific Officer,  In Silico Biosciences, USA
• CSF biomarker changes precede symptom onset of mild cognitive impairment. Dr Abhay Moghekar, Asst. Professor of Neurology,  Johns Hopkins University School of Medicine, USA